ClinicalTrials.gg
RecruitingNCT07657988CLEARUpdated Jun 18, 2026

Outcomes Associated With Tirbanibulin for Large Field Application on the Face in the U.S (CLEAR)

An observational study in Actinic Keratosis (AK), sponsored by Avant Health LLC. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Avant Health LLC · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 165 studies in Keratosis, Actinic with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Keratosis, Actinic · United States.

Planned enrollment
10th of 11
30 · median 117
Started
2026
with 10 others
Observational
12 of 165
1 open now
Primary completion
2026-10
later than 3 of 20 live
Registered
162nd of 165
by date

Among the 165 studies in Keratosis, Actinic with a site in United States, this one is the 10th largest by planned enrollment of the 11 observational ones that give a count, is one of 11 that started in 2026, is one of 12 observational ones, reaches primary completion later than 3 of the 20 other live ones, and was the 162nd registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 30 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

16 of the 165 studies in Keratosis, Actinic with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Keratosis, Actinic studies recruiting now, 17 (77%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Keratosis, Actinic with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the effectiveness of tirbanibulin among adult subjects with actinic keratosis (AK) lesions in the face. The main question it aim to answer is:

How does tirbanibulin improve subject's overall appearance of the skin, improve how patient's skin looks, and improve patient's skin texture, in a 57-day observation period.

Participants already taking tirbanibulin as part of their regular medical care for AK will answer online survey questions at the beginning of the study and at Day 57.

03

Conditions studied

  • Actinic Keratosis (AK)

Keywords

  • tirbanibulin
  • Actinic Keratosis
  • Overall Appearance
  • Skin Texture
  • Skin Quality
  • IGA
  • Satisfaction
  • Preference
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study-eligible AK patients receiving usual care treatment in routine clinical practices in the U.S.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with AK on the face.
  • Has clinically typical, visible, and discrete 4-12 AK lesions on the face.
  • Considered as a potential candidate for tirbanibulin (Klisyri®) treatment to manage their AK lesions on the face.
  • Male or female, aged 18 years and above at the time of initiation of treatment with tirbanibulin.
  • Willing to avoid excessive sun or UV exposure, and/or use relevant sunscreen protection and protective clothing during the study duration.
  • Able to read and write in English.
  • Provide consent to participate in the study.
  • Willing to comply with all study procedures (including photography tasks) and be available for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with any dermatological condition of the face that could interfere with clinical evaluations.
  • Hypertrophic AK lesions, open wounds, or suspected skin cancers within proximity of the treatment area.
  • Anticipated need for in-patient hospitalization or in-patient surgery within the next 2 months.
  • Patients unable to comply with the requirements of the study or patients who, in the opinion of the study physician should not participate in the study.
  • Patients for whom medical chart is inaccessible to physicians to complete baseline data collection.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Tirbanibulin

    Participants will receive tirbanibulin ointment 3.5 mg in 350 mg (as 1 single-dose packet per application, for 5 consecutive days). The participants will be observed for 57 days to gather participant reported outcomes (PROs) and clinical profile.

    Drug: Tirbanibulin

Interventions

  • Participants receiving tirbanibulin ointment 1% (3.5 mg tirbanibulin in 350 mg) as 1 single-dose packet per application, for 5 consecutive days

    Also known as: Klisyri®

06

What researchers measure

Primary outcomes

  1. Subject and clinician rating of current 'overall appearance of the skin' in the original AK treated area

    The overall appearance of the skin in the original AK treated area (in comparison to baseline) is rated on a 5-point Likert scale of much worse, somewhat worse, no change, somewhat improved, much improved.

    Time frame: At end of study observation period, at day 57

  2. Subject and clinician rating of their satisfaction with the ability of tirbanibulin treatment to 'improve how skin looks' and 'improve skin texture' respectively, in the original AK treated area

    Satisfaction is rated on a 7-point Likert scale of extremely satisfied, very satisfied, dissatisfied, somewhat satisfied, satisfied, very satisfied, extremely satisfied.

    Time frame: At the end of study observation period, at day 57

Secondary outcomes

  1. Proportion of Subjects with IGA success, defined as an IGA score of completely cleared (0) or partially cleared (1) in AK status in the treated area

    Time frame: At the end of study observation period, at day 57

07

Study locations

2 of 2 sites recruiting
  • Ablon Skin Institute and Research Center
    Manhattan Beach, California 90266, United States
    Recruiting
  • Dermatology & Laser Center of Charleston
    Charleston, South Carolina 29414, United States
    Recruiting
    • Todd Schlesinger, MD · Contactskindoc@dermandlaser.com · 843.377.2201
    • Todd Schlesinger, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.

Of 17 observational studies under Keratosis, Actinic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 18, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07657988
Lead sponsor
Avant Health LLC
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Apr 2, 2026
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jun 18, 2026

Study contacts

Siva Narayanan, PhD, MPhil, MHS, MSc
Contact
info@avant-health.com
301-799-AVANT
Siva Narayanan, PhD, MPhil, MHS, MSc
study chair · Avant Health LLC
Todd Schlesinger, MD
principal investigator · Avant Health LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion